# PTT-936 Alone or in Combination in Patients With Locally Advanced or Metastatic Solid Tumors

Source: https://onco.cc/trials/nct06244992/  
OnCo record `nct06244992` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of PTT-936 in advanced solid tumours, run by Pyrotech Therapeutics, Inc., now recruiting.

## Summary

PTT-936 Alone or in Combination in Patients With Locally Advanced or Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT06244992 by Pyrotech Therapeutics, Inc., with 68 participants planned, started 2024-01-26 and due to reach its primary completion in 2027-09-30. Interventions recorded: PTT-936 and Combination of PTT-936 and anti-PD-1/L1 therapy.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06244992
- Phase: 1/2
- Setting: A Phase 1/2a Study to Evaluate the Safety, Pharmacokinetics and Efficacy of PTT-936, an Alpha Kinase 1 (ALPK1) Activator, Alone or in Combination With Anti-PD-1/L1 in Patients With Locally Advanced or Metastatic Solid Tumors
- Sponsor: Pyrotech Therapeutics, Inc.
- Enrolled: 68

## Sources

- ClinicalTrials.gov NCT06244992: https://clinicaltrials.gov/study/NCT06244992

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)

---
JSON: https://onco.cc/api/v1/entities/nct06244992.json